Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetics Generation AdvancementROCO:4160 -2.43%70 Shareholder Yield % is 4.03% as of Dec. 2025, which is 660% above its 10-year median of 0.53. GuruFocus rates ROCO:4160 with a GF Score™ of 70/100 and a GF Value™ of NT$51.36 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Genetics Generation Advancement ranks better than 80.88% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Genetics Generation Advancement's Shareholder Yield % was 4.03%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Genetics Generation Advancement Shareholder Yield % Related Terms
Genetics Generation Advancement Shareholder Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4160 vs TMO, DHR, IDXX: Shareholder Yield % Comparison
For the Diagnostics & Research subindustry, Genetics Generation Advancement's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetics Generation Advancement Shareholder Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Genetics Generation Advancement's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Genetics Generation Advancement (ROCO:4160) has a Shareholder Yield % of 4.03% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Genetics Generation Advancement and its competitors. This is 660% above median its historical median of 0.53. According to the industry distribution chart, Genetics Generation Advancement ranks #39 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 19.1%.
Is Genetics Generation Advancement's Shareholder Yield % too high?
Genetics Generation Advancement's current Shareholder Yield % of 4.03% is 660% above median its 10-year median of 0.53. Based on the distribution chart, Genetics Generation Advancement ranks #39 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Genetics Generation Advancement has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's Shareholder Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetics Generation Advancement ranks #39 out of 204 companies for Shareholder Yield %. This places Genetics Generation Advancement in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Medical Diagnostics & Research company?
A good Shareholder Yield % depends on the Medical Diagnostics & Research industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Genetics Generation Advancement and its competitors. Genetics Generation Advancement's current Shareholder Yield % is 4.03%, which is 660% above median its own 10-year median of 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$51.36, compared to a current price of NT$40.15 — trading 21.8% below its estimated fair value. The current Shareholder Yield % is 4.03%, which is 660% above median its 10-year median of 0.53. Genetics Generation Advancement's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current Shareholder Yield % is 4.03% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?
Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued.
The current stock price of NT$40.15 is trading 21.8% below its estimated GF Value™ of NT$51.36.
GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.
Key valuation signals for ROCO:4160:
Shareholder Yield %: 4.03% (660% above median its 10-year median of 0.53)
GF Value™: NT$51.36 vs. price of NT$40.15 (21.8% below fair value)
No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetics Generation Advancement Business Description
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
70GF Score
Get the complete analysis for ROCO:4160
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4160 has been successfully added to your 
